The biggest cost of the trade war — less access to Chinese vaccines

From my Bloomberg column:

The current portfolio is multinational, including investments in Pfizer, Sanofi, AstraZeneca and Johnson & Johnson. Ideally, there should be at least one Chinese vaccine included, but there is not.

Obviously, given the rhetoric of the current administration, using a Chinese vaccine would be politically difficult. You can’t call it “the Chinese virus” and then tell Americans they ought to take a Chinese vaccine. So the Trump administration has made no serious effort to make a vaccine-sharing deal with China.

And:

The matter is hardly settled, but at the very least the Chinese vaccines are not dropping out of contention.

Note that a year’s worth of partial protection still could go a long way.  Recommended.

Comments

Respond

Add Comment